Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Regeneron Pharma (REGN) PT Raised to $640 at Cowen
February 4, 2022 12:55 PM ESTCowen analyst Tyler Van Buren raised the price target on Regeneron Pharma (NASDAQ: REGN) to $640.00 (from $625.00) while maintaining a Market Perform rating following reuslts.
The analyst commented, "A strong commercial performance of the core business led to strong Q4 results. Understanding... More
Regeneron (REGN) Tops Q4 EPS by $5.35
February 4, 2022 6:31 AM ESTRegeneron (NASDAQ: REGN) reported Q4 EPS of $23.72, $5.35 better than the analyst estimate of $18.37. Revenue for the quarter came in at $4.95 billion versus the consensus estimate of $4.42 billion.
2022 Financial... More
